Loading..

Mersana Therapeutics, Inc. (MRSN) Report Analysis

Corporate Events

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropp...

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2000 Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropp...

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Small Cap Comp Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropp...

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000 Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropp...

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000E Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropp...

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Microcap Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropp...

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2500 Growth Index

Neutral

Mersana Therapeutics, Inc. Presents at 3rd Annu...

2022-05-26 12:00:00

Mersana Therapeutics, Inc. Presents at 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun-02-2022 01:00 PM.

Neutral

Mersana Therapeutics, Inc. Presents at 2022 Jef...

2022-05-26 12:00:00

Mersana Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 10:00 AM. Venue: Marriott Marquis, New York Ci...

Neutral

Mersana Therapeutics, Inc. Presents at The JMP ...

2022-05-09 14:47:00

Mersana Therapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:00 PM. Venue: Lotte New York Palace, 4...

Neutral

Mersana Therapeutics, Inc., Q1 2022 Earnings Ca...

2022-05-02 12:00:00

Mersana Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022

Neutral

Mersana Therapeutics, Inc. to Report Q1, 2022 R...

2022-05-02 12:00:00

Mersana Therapeutics, Inc. announced that they will report Q1, 2022 results on May 09, 2022

Neutral

Mersana Therapeutics, Inc., Annual General Meet...

2022-04-29 10:08:00

Mersana Therapeutics, Inc., Annual General Meeting, Jun 09, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider directorate reelectio...

Neutral

Mersana Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-29 10:08:00

AGM

Neutral

Mersana Therapeutics, Inc. Presents at AACR Ann...

2022-04-05 12:00:00

Mersana Therapeutics, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022. Venue: Ernest N. Morial Convention Center, N...

Positive

Mersana Therapeutics, Inc. to Present Preclinic...

2022-04-05 12:00:00

Mersana Therapeutics, Inc. announced that it will present three posters highlighting data for XMT-1660, XMT-2056, and the Immunosynthen ADC pl...

Neutral

Cowen Inc., 3rd Annual Oncology Innovation Summ...

2022-03-28 15:12:00

Cowen Inc., 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun 02, 2022.

Neutral

JMP Securities LLC, the JMP Securities Life Sci...

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Mad...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Mersana Therapeutics, Inc. Presents at SLAS 202...

2022-02-05 10:28:00

Mersana Therapeutics, Inc. Presents at SLAS 2022 International Conference and Exhibition, Feb-08-2022 04:00 PM. Venue: Boston Convention and E...

Positive

Mersana Therapeutics, Inc. Announces Research C...

2022-02-03 12:00:00

Mersana Therapeutics, Inc. announced a research collaboration and license agreement with Janssen Biotech, Inc. to discover novel ADCs for thre...

Neutral

American Association For Cancer Research, AACR ...

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Cent...

Neutral

Society for Laboratory Automation & Screening, ...

2021-12-28 18:17:00

Society for Laboratory Automation & Screening, SLAS 2022 International Conference and Exhibition, Feb 05, 2022 through Feb 09, 2022. Venue: Bo...

Neutral

Mersana Therapeutics, Inc. Presents at 4th Annu...

2021-11-23 13:00:00

Mersana Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:40 PM.

Neutral

Mersana Therapeutics, Inc. Presents at Stifel 2...

2021-11-10 13:02:00

Mersana Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 03:20 PM. Venue: New York, New York, United Stat...

Neutral

Mersana Therapeutics, Inc. has filed a Shelf Re...

2021-11-09 00:00:00

Mersana Therapeutics, Inc. has filed a Shelf Registration in the amount of $300 million. Security Name: Common Stock Security Name: Pref...

Neutral

Mersana Therapeutics, Inc., Q3 2021 Earnings Ca...

2021-11-02 12:00:00

Mersana Therapeutics, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Positive

Mersana Therapeutics, Inc. Enters into A Loan a...

2021-10-29 21:25:00

On October 29, 2021 Mersana Therapeutics, Inc. entered into a Loan and Security Agreement (the Loan Agreement") by and among the Company, Oxfo...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Negative

Mersana Therapeutics, Inc. Appoints Mohan Bala ...

2021-10-25 12:00:00

Mersana Therapeutics, Inc. announced the appointment of Mohan Bala as SVP, Strategic Product Planning & Program Leadership, effective October...

Neutral

Mersana Therapeutics, Inc. Presents at Antibody...

2021-10-06 12:38:00

Mersana Therapeutics, Inc. Presents at Antibody Engineering & Therapeutics US, Dec-16-2021 10:30 AM. Venue: Marriott Marquis San Diego, San Di...

Positive

Mersana Therapeutics to Announce Target and Pre...

2021-09-30 12:00:00

Mersana Therapeutics, Inc. announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen S...

Neutral

Mersana Therapeutics, Inc. Presents at 2021 AAC...

2021-09-30 12:00:00

Mersana Therapeutics, Inc. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-...

Neutral

Mersana Therapeutics, Inc. Presents at Morgan S...

2021-09-07 16:42:00

Mersana Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 01:15 PM. Venue: New Windsor, Unit...

Neutral

Mersana Therapeutics, Inc. Presents at Cantor G...

2021-09-07 12:00:00

Mersana Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:00 PM. Venue: New York, United States.

Neutral

Mersana Therapeutics, Inc. - Special Call

2021-09-01 12:00:00

To discuss the progress of its clinical development strategy for upifitamab rilsodotin (UpRi) and report updated interim data from the ovarian...

Neutral

Mersana Therapeutics, Inc. Presents at Baird Gl...

2021-08-26 17:20:00

Mersana Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 08:30 AM. Speakers: Anna Protopapas, President, CE...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Negative

Mersana Therapeutics, Inc. Announces Executive Changes

2021-08-16 12:00:00

Mersana Therapeutics, Inc. announced the appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer, effective August 16, 2021. Dr. Mi...

Neutral

American Association For Cancer Research, Natio...

2021-08-11 12:00:00

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2...

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

Mersana Therapeutics, Inc. Presents at BTIG Vir...

2021-08-04 12:33:00

Mersana Therapeutics, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:00 AM. Speakers: Anna Protopapas, President, CEO ...

Neutral

Mersana Therapeutics, Inc. Presents at 12th Ann...

2021-08-04 12:00:00

Mersana Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:20 PM. Speakers: Timothy B. L...

Neutral

Mersana Therapeutics, Inc., Q2 2021 Earnings Ca...

2021-07-30 12:00:00

Mersana Therapeutics, Inc., Q2 2021 Earnings Call, Aug 06, 2021

Positive

Mersana Therapeutics Announces Initiation of th...

2021-07-28 12:00:00

Mersana Therapeutics, Inc. announced the initiation of patient dosing in UPGRADE, a Phase 1 combination dose escalation umbrella study to eval...

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conferenc...

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Neutral

Wedbush Securities Inc., 12th Annual Wedbush Pa...

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2000 Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2000 Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Small Cap Comp Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Small Cap Comp Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000 Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000 Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000E Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 3000E Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Microcap Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell Microcap Growth Index

Negative

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2500 Growth Index

2022-06-24 00:00:00

Mersana Therapeutics, Inc.(NasdaqGS:MRSN) dropped from Russell 2500 Growth Index

Neutral

Mersana Therapeutics, Inc. Presents at 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun-02-2022 01:00 PM

2022-05-26 12:00:00

Mersana Therapeutics, Inc. Presents at 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun-02-2022 01:00 PM.

Neutral

Mersana Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 10:00 AM

2022-05-26 12:00:00

Mersana Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Mersana Therapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:00 PM

2022-05-09 14:47:00

Mersana Therapeutics, Inc. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 03:00 PM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Neutral

Mersana Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022

2022-05-02 12:00:00

Mersana Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022

Neutral

Mersana Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

2022-05-02 12:00:00

Mersana Therapeutics, Inc. announced that they will report Q1, 2022 results on May 09, 2022

Neutral

Mersana Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

2022-04-29 10:08:00

Mersana Therapeutics, Inc., Annual General Meeting, Jun 09, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider directorate reelections; to consider to reelect its auditor for the fiscal year December 31, 2022; and to consider other matters.

Neutral

Mersana Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-29 10:08:00

AGM

Neutral

Mersana Therapeutics, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022

2022-04-05 12:00:00

Mersana Therapeutics, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States. Presentation Date(s): Apr-11-2022. Apr-12-2022.

Positive

Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting

2022-04-05 12:00:00

Mersana Therapeutics, Inc. announced that it will present three posters highlighting data for XMT-1660, XMT-2056, and the Immunosynthen ADC platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held in New Orleans, Louisiana from April 8-13, 2022. XMT-1660 is a Dolasynthen ADC targeting B7-H4, a target selectively expressed on tumors in areas of high unmet medical need, including breast, endometrial, ovarian and other cancers. The data show that a single dose of XMT-1660 has anti-tumor activity in both triple-negative breast cancer (TNBC) and estrogen receptor (ER)-positive breast cancer xenograph models. Higher B7-H4 expression is associated with greater anti-tumor activity of XMT-1660 in preclinical studies. Mersana expects a Phase 1 clinical trial for XMT-1660 to start in mid-2022. XMT-2056, Mersana’s first Immunosynthen STING-agonist ADC, targets a novel epitope of HER2, and is designed to offer a differentiated and complementary therapeutic approach to the treatment of HER2-expressing tumors. The preclinical data presented show that XMT-2056 demonstrates robust anti-tumor activity as a monotherapy in both HER2-high and HER2-low expressing models. XMT-2056’s complementary mechanism of action results in increased efficacy in combination with trastuzumab, pertuzumab, anti-PD-1, or trastuzumab deruxtecan in preclinical studies. Mersana expects to initiate a Phase 1 clinical trial of XMT-2056 in mid-2022. Immunosynthen is Mersana’s immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Data show that anti-tumor activity of Immunosynthen STING-agonist ADCs involves the targeted activation of the STING pathway in an antigen binding-dependent manner in both tumor-resident immune cells and in tumor cells. In addition to delivery to the tumor cell via antigen binding and internalization, data from multiple models demonstrate Fc?-R1 is the major receptor that mediates delivery to a specific population of myeloid cells resident in primary human tumors, eliciting potent anti-tumor responses in preclinical studies.

Neutral

Cowen Inc., 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun 02, 2022

2022-03-28 15:12:00

Cowen Inc., 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA, Jun 02, 2022.

Neutral

JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022

2022-02-16 16:45:00

JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Mersana Therapeutics, Inc. Presents at SLAS 2022 International Conference and Exhibition, Feb-08-2022 04:00 PM

2022-02-05 10:28:00

Mersana Therapeutics, Inc. Presents at SLAS 2022 International Conference and Exhibition, Feb-08-2022 04:00 PM. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States. Speakers: Kalli Catcott, Naniye Malli.

Positive

Mersana Therapeutics, Inc. Announces Research Collaboration and License Agreement with Janssen Biotech, Inc. to Advance Novel Antibody-Drug Conjugates

2022-02-03 12:00:00

Mersana Therapeutics, Inc. announced a research collaboration and license agreement with Janssen Biotech, Inc. to discover novel ADCs for three targets. The agreement was facilitated by Johnson & Johnson Innovation. Under the terms of the agreement, Janssen will provide proprietary antibodies for three targets. Mersana will apply its expertise and its proprietary Dolasynthen platform to discover novel ADC product candidates. Mersana may leverage Synaffix’s GlycoConnectTM technology as its preferred site-specific ADC bioconjugation technology. Mersana will collaborate with Janssen on target candidates during preclinical development, with Janssen being solely responsible for clinical development and commercialization. Mersana will receive an upfront payment of $40 million. Mersana is eligible to receive reimbursement of certain costs as well as more than $1 billion in potential milestone payments, plus mid-single-digit to low double-digit percentage royalties on worldwide net sales of ADCs against the selected targets.

Neutral

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Neutral

Society for Laboratory Automation & Screening, SLAS 2022 International Conference and Exhibition, Feb 05, 2022 through Feb 09, 2022

2021-12-28 18:17:00

Society for Laboratory Automation & Screening, SLAS 2022 International Conference and Exhibition, Feb 05, 2022 through Feb 09, 2022. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States.

Neutral

Mersana Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:40 PM

2021-11-23 13:00:00

Mersana Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:40 PM.

Neutral

Mersana Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 03:20 PM

2021-11-10 13:02:00

Mersana Therapeutics, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-17-2021 03:20 PM. Venue: New York, New York, United States. Speakers: Anna Protopapas, President and Chief Executive Officer.

Neutral

Mersana Therapeutics, Inc. has filed a Shelf Registration in the amount of $300 million.

2021-11-09 00:00:00

Mersana Therapeutics, Inc. has filed a Shelf Registration in the amount of $300 million. Security Name: Common Stock Security Name: Preferred Stock Security Name: Warrants Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Neutral

Mersana Therapeutics, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-11-02 12:00:00

Mersana Therapeutics, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Positive

Mersana Therapeutics, Inc. Enters into A Loan and Security Agreement

2021-10-29 21:25:00

On October 29, 2021 Mersana Therapeutics, Inc. entered into a Loan and Security Agreement (the Loan Agreement") by and among the Company, Oxford Finance LLC, in its capacity as collateral agent (in such capacity, the Agent") and a lender, and Silicon Valley Bank as a lender (collectively, the Lenders"), pursuant to which term loans of up to an aggregate principal amount of $100.0 million is available to the Company, consisting of (i) a tranche A term loan in the aggregate principal amount of up to $60.0 million available at any time on or prior to December 31, 2022 at the option of the Company, $25.0 million of which was disbursed on the Closing Date and utilized, in part, to repay existing indebtedness of the Company; (ii) a contingent tranche B term loan in the aggregate principal amount of $10.0 million available to the Company at any time on or prior to December 31, 2022, within 90 days of the Company having both (x) enrolled and dosed the first patient in a Phase I trial for XMT-2056 and (y) enrolled and dosed the first patient in a Phase I trial for XMT-1660, so long as the UpRi UPLIFT cohort intended to support a submission of a Biologics License Application is ongoing; (iii) a contingent tranche C term loan in the aggregate principal amount of $10.0 million available to the Company at any time on or prior to June 30, 2023, within 90 days of the Company having received positive data from the UpRi UPLIFT registrational trial sufficient to support a Biologics License Application; and (iv) a contingent tranche D term loan in the aggregate principal amount of $20.0 million available at any time on or prior to November 1, 2024 (extended to November 1, 2025 if the tranche C term loan milestone is achieved), which is available in the sole discretion of the Lenders, subject, in each case of the foregoing, to certain other terms and conditions.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Negative

Mersana Therapeutics, Inc. Appoints Mohan Bala as SVP, Strategic Product Planning & Program Leadership

2021-10-25 12:00:00

Mersana Therapeutics, Inc. announced the appointment of Mohan Bala as SVP, Strategic Product Planning & Program Leadership, effective October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana’s principal financial officer. Mohan Bala, Ph.D., was most recently Chief Operating Officer at Constellation Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics to address patients with cancers associated with abnormal gene expression. While at Constellation, Dr. Bala was responsible for overall asset strategy and program management. Prior to joining Constellation, Dr. Bala served as VP, Development Program Lead at TESARO, where he led cross-functional teams to advance two products to Phase 2 and one product to regulatory filing. He has been involved in multiple successful BLA and MAAs, including the filing of a companion diagnostic. Earlier in his career, Dr. Bala held senior leadership roles at Sanofi, GlaxoSmithKline and Centocor.

Neutral

Mersana Therapeutics, Inc. Presents at Antibody Engineering & Therapeutics US, Dec-16-2021 10:30 AM

2021-10-06 12:38:00

Mersana Therapeutics, Inc. Presents at Antibody Engineering & Therapeutics US, Dec-16-2021 10:30 AM. Venue: Marriott Marquis San Diego, San Diego, California, United States. Speakers: Timothy B. Lowinger, Chief Science & Technology Officer.

Positive

Mersana Therapeutics to Announce Target and Present New Preclinical Data for Xmt-2056 At the Aacr-Nci-Eortc Virtual International Conference on Molecular Targets and Cancer Therapeutics

2021-09-30 12:00:00

Mersana Therapeutics, Inc. announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

Neutral

Mersana Therapeutics, Inc. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 12:50 PM

2021-09-30 12:00:00

Mersana Therapeutics, Inc. Presents at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct-07-2021 12:50 PM. Speakers: Timothy B. Lowinger, Chief Science & Technology Officer.

Neutral

Mersana Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 01:15 PM

2021-09-07 16:42:00

Mersana Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 01:15 PM. Venue: New Windsor, United States.

Neutral

Mersana Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:00 PM

2021-09-07 12:00:00

Mersana Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:00 PM. Venue: New York, United States.

Neutral

Mersana Therapeutics, Inc. - Special Call

2021-09-01 12:00:00

To discuss the progress of its clinical development strategy for upifitamab rilsodotin (UpRi) and report updated interim data from the ovarian cancer expansion cohort of the UpRi Phase 1 study. Enrollment in the expansion cohort is complete with 97 patients evaluable for safety and tolerability, of which 75 are RECIST-evaluable at this interim analysis

Neutral

Mersana Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 08:30 AM

2021-08-26 17:20:00

Mersana Therapeutics, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 08:30 AM. Speakers: Anna Protopapas, President, CEO & Director.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Negative

Mersana Therapeutics, Inc. Announces Executive Changes

2021-08-16 12:00:00

Mersana Therapeutics, Inc. announced the appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer, effective August 16, 2021. Dr. Misra replaces Michael Kaufman, Ph.D., who is retiring from Mersana after more than five years with the Company. Dr. Kaufman will remain at Mersana to ensure a smooth transition until September 10, 2021. Tushar Misra, Ph.D., was most recently EVP, Head of Technical Development & Manufacturing at Laronde. While at Laronde, he led the process development and support team for end-to-end manufacturing for preclinical and clinical research. Before that, he was SVP, Technical Operations at Wave Life Sciences. Prior to Wave Life Sciences, Dr. Misra worked at Takeda Pharmaceuticals in several positions of increasing seniority, most recently as VP & Head, Global Oncology and Biologics Operations. While at Takeda, he built world-wide manufacturing and supply chain infrastructure for the company’s biologic and oncology commercial products including ADCETRIS® (brentuximab vedotin) and ENTYVIO (vedolizumab). Earlier in his career, he held senior executive leadership roles in Chemistry and Pharmaceutical Sciences at Sunovion Pharmaceuticals, Inc. (previously Sepracor, Inc.).

Neutral

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct 07, 2021 through Oct 11, 2021

2021-08-11 12:00:00

American Association For Cancer Research, National Cancer Institute, The European Organisation For Research and Treatment of Cancer (eortc), 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct 07, 2021 through Oct 11, 2021.

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

Mersana Therapeutics, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:00 AM

2021-08-04 12:33:00

Mersana Therapeutics, Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:00 AM. Speakers: Anna Protopapas, President, CEO & Director, Arvin Yang, Senior VP & Chief Medical Officer, Brian C. DeSchuytner, Senior Vice President of Finance & Product Strategy, James Salierno, Investor Relations, Sarah Carmody, Executive Director of Investor Relations & Corporate Communications, Timothy B. Lowinger, Chief Science & Technology Officer.

Neutral

Mersana Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:20 PM

2021-08-04 12:00:00

Mersana Therapeutics, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 02:20 PM. Speakers: Timothy B. Lowinger, Chief Science & Technology Officer.

Neutral

Mersana Therapeutics, Inc., Q2 2021 Earnings Call, Aug 06, 2021

2021-07-30 12:00:00

Mersana Therapeutics, Inc., Q2 2021 Earnings Call, Aug 06, 2021

Positive

Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer

2021-07-28 12:00:00

Mersana Therapeutics, Inc. announced the initiation of patient dosing in UPGRADE, a Phase 1 combination dose escalation umbrella study to evaluate the safety and efficacy of upifitamab rilsodotin (UpRi, previously XMT-1536) in combination with other ovarian cancer therapies. The initial arm of this umbrella study is evaluating carboplatin in combination with UpRi followed by continuation of UpRi monotherapy in patients with platinum-sensitive ovarian cancer. The UPGRADE Phase 1, open-label, dose-escalation portion of the study will determine the maximum tolerated dose (MTD) and safety and tolerability of a once-every-four-week (Q4W) administration of UpRi in combination with carboplatin for six cycles followed by continuation of UpRi monotherapy in patients with platinum-sensitive high-grade serous ovarian cancer following 1-2 prior platinum-based regimens. Patients will not be preselected for NaPi2b expression; however, archival or fresh tissue will be required for retrospective assessment of expression. Upon completion of the dose-escalation portion of the study, the Company plans to initiate the expansion portion to assess both tolerability and efficacy and inform the further development of UpRi in a broader and earlier-line patient population.

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Neutral

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021

2021-06-29 20:28:00

Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.

Fundamental Summary

At a high level, the metrics from Mersana Therapeutics's Q1 financial report release were demonstrably negative. Specifically, their growth, value, and income factors indicate an execution challenge when it comes to generating exciting and consistent growth. These results suggest a challenging future for Mersana Therapeutics's stock. Correspondingly, Mersana Therapeutics received a ranking of 50 and a UNDERPERFORM recommendation.

Mersana Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 47.26 million compared to USD 34.69 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.5 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to USD 0.5 a year ago.

Business Description

Mersana Therapeutics, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics in November 2005. Mersana Therapeutics was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Sector Overview

Mersana Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Mersana Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 258.3 25.3% 68
Liabilities 117.7 39.6% 75
Price to Book 2.8 -24.6% 52
Cash & Equivalents 230.1 29.3% 82
Equity 140.5 15.4% 39
EBITDA -176.3 -7.2% 54
Total Revenues 2.1 4709.3% 37
Parameter Value Change Score
Return on Equity -107.9 -11.0% 72
Net Cashflow 1.8 102.3% 59
Capital Expenditure -0.9 -33.2% 53
Asset Turnover 0.0 4464.8% 92
Free Cashflow -1.7 16.6% 69

* All values are TTM

The below chart reflects Mersana Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Mersana Therapeutics's peer average final assessment score stands on 57.0, Mersana Therapeutics's score is 50.

  •  MRSN
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 36 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 37 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 38 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 39 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Mersana Therapeutics's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Mersana Therapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.

Bearish 57
Close Price 4.63
52W Low 2.84
52W High 14.47
5D MA 4.8
50D MA 3.61
200D MA 5.73
MACD 0.35
RSI 13.45
STOCH 81.68

Balance Sheet Analysis

Several numbers from Mersana Therapeutics's current balance sheet were concerning, in two areas in particular: Equity and Book Value Factors. Mersana Therapeutics management produced disappointing equity metrics this period, which stood at 140.5, representing a 15.4% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Its equity movement component, therefore, received a grade of 39. Also, Mersana Therapeutics publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as 2.8, representing a -24.6% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Therefore, their book value factors earned a score of 52. That said, one metric, Cash & Equivalents, stood out as strongly positive. Mersana Therapeutics's management was effective in improving its cash and cash equivalents metrics, which now sit at 230.1. This represents 29.3% change from the last reporting period. This performance is significantly more impressive than its peers and competitors. It suggests that their stock price has room to grow to reflect its actual intrinsic value. The company's cash and cash equivalents movement, therefore, received a grade of 82. The company's balance sheet, Therefore, earned a score of 58.

Parameter Value Change Score
Assets 258.3 25.3% 68
Liabilities 117.7 39.6% 75
Price to Book 2.8 -24.6% 52
Cash & Equivalents 230.1 29.3% 82
Equity 140.5 15.4% 39
* All values are TTM

The below chart describes Mersana Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Mersana Therapeutics received a balance sheet score of 58, the average of its peers stands on 60.0.

  •  MRSN
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 36 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 37 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 38 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 39 1
Geron Corporation 566.2M 69 72 37 59 62 60 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

A deep look into Mersana Therapeutics's income statement metrics showed some disappointing metrics. The most troubling factors we're looking at are the Revenue Efficiency and EBITDA . Mersana Therapeutics's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 37. Also, Mersana Therapeutics reported concerning EBITDA this period. At filing, EBITDA was reported as -176.3, representing -7.2% change from the previous period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. Their EBITDA metrics are even more problematic when compared to their peers. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 54. On the other hand, Return Factors, jumped out as looking rather positive. Mersana Therapeutics's reported return on equity (ROE) ratio was -107.9, representing a change of -11.0%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 72. Therefore, it received a cautionary score of 47.

Parameter Value Change Score
EBITDA -176.3 -7.2% 54
Total Revenues 2.1 4709.3% 37
Return on Equity -107.9 -11.0% 72
* All values are TTM

The below chart describes Mersana Therapeutics's performance as reflected on its income statement with respect to its peers. While Mersana Therapeutics received a income statement score of 47 , the average of its peers stands on 58.0.

  •  MRSN
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 36 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 37 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 38 1
AnaptysBio, Inc. 586.3M 97 50 77 68 39 1
Geron Corporation 566.2M 89 67 73 78 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Mersana Therapeutics appears likely to maintain its strong cash flow metrics and momentum going forward. Mersana Therapeutics's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Mersana Therapeutics recorded asset turnover of 0.0, which represents a 4464.8% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. The company's asset turnover movement, therefore, received a grade of 92. Also, Mersana Therapeutics's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Mersana Therapeutics recorded free cash flow of -1.7, which represents a 16.6% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. Therefore, its free cash flow movement earned a score of 69. However, one discouraging result, Capital Expenditure, stood out. Mersana Therapeutics's published capital expenditures (CapEx) numbers were discouraging and reflected management's unbalanced growth strategy. Mersana Therapeutics recorded CapEx of -0.9, which represents a -33.2% change from the previous report. This performance is all the more uninspiring relative to their peers and competitors. Its CapEx movement, therefore, received a grade of 53. Its cash flow, therefore, earned a score of 65.

Parameter Value Change Score
Net Cashflow 1.8 102.3% 59
Capital Expenditure -0.9 -33.2% 53
Asset Turnover 0.0 4464.8% 92
Free Cashflow -1.7 16.6% 69
* All values are TTM

The below chart describes Mersana Therapeutics's performance as reflected on its cash flow with respect to its peers. While Mersana Therapeutics received a cash flow score of 65, the average of its peers stands on 65.0.

  •  MRSN
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 36 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 37 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 38 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 39 1
Geron Corporation 566.2M 78 68 49 81 77 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.